We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits

By LabMedica International staff writers
Posted on 12 Mar 2026

Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. More...

A new study shows that different at-home gut health tests—and even repeated tests from the same provider—can produce conflicting bacterial abundance estimates and divergent health categorizations. The findings highlight persistent gaps in standardization.

In work from the National Institute of Standards and Technology, (NIST; Gaithersburg, MD, USA) investigators evaluated commercially available, direct-to-consumer gut microbiome testing kits. These services analyze an individual’s fecal sample to profile microbiome composition and, in many cases, convert those data into health assessments. The team focused on analytical performance across brands and replicate submissions to understand how methodological differences affect reported results.

The study assessed 21 test kits from seven anonymized providers, all analyzing the same combined fecal sample from a single donor. Reported relative abundances of specific taxa varied widely between companies, with the genus Clostridium—encompassing pathogens such as Clostridioides difficile—among the most variable findings. For context, the American Gut Project’s average abundance for Clostridium was just over 2.5%, yet one company reported approximately five times that level, while three others failed to detect the genus in one or more submissions. Within-brand consistency also diverged: three identical samples sent to the same provider yielded conflicting health categorizations, with one labeled “unhealthy” and two labeled “healthy.”

The authors attribute the discrepancies to nonstandardized sampling procedures, sample processing and analysis pipelines, and the distinct metrics individual companies apply to generate health scores. They propose that standardizing sampling protocols and testing methods could improve the accuracy and interpretability of direct-to-consumer microbiome testing. The findings are published in Communications Biology on February 26, 2026.

Related Links
National Institute of Standards and Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.